NDAC 61-02-09-02
Continuous quality improvement program
Cite as N.D. Admin. Code ยง 61-02-09-02
1.
Each pharmacy permittee shall establish continuous quality improvement program for the
purpose of detecting, documenting, assessing, and preventing incidents, near misses, and
unsafe conditions.
2.
A pharmacy permittee meets the requirements if the permittee meets the following:
a.
Maintains and complies with the policies and procedures as noted in subsection 4;
b.
The pharmacy reports incidents, near misses, and unsafe events through either:
(1)
A contracted patient safety organization that is listed as an agency for health
research and quality on www.ahrq.com whose primary mission is pharmacy
continuous quality improvement; or
(2)
An internal program to the pharmacy which is acceptable to the board where proper
documentation and evaluation can be completed.
3.
At a minimum, a continuous quality improvement program must include provisions to:
a.
Designate an individual or individuals responsible for implementing, maintaining, and
monitoring the continuous quality improvement program, which is managed in
accordance with written policies and procedures maintained in the pharmacy in an
immediately retrievable form;
b.
Initiate documentation of incidents, near misses, and unsafe conditions as soon as
possible, but no more than seven days, after determining their occurrence;
4.
The policies and procedures must be in compliance with this section must include:
a.
Training all pharmacy personnel in relevant phases of the continuous quality
improvement program;
b.
Identifying and documenting reportable incidents and near misses and unsafe events;
c.
Minimizing the impact of incidents and near misses and unsafe events on patients;
d.
Analyzing data collected to assess the causes and any contributing factors relating to
incidents and near misses and unsafe events;
e.
Use the findings to formulate an appropriate response and to develop pharmacy systems
and workflow processes designed to prevent and reduce incidents and near misses and
unsafe events; and
f.
Periodically, but at least quarterly, meet with appropriate pharmacy personnel to review
findings and inform personnel of changes that have been made to pharmacy policies,
procedures, systems, or processes as a result of continuous quality improvement
program findings.
5.
Quality self-audit. Each pharmacy shall conduct a quality self-audit at least quarterly to
determine whether the occurrence of incidents, near misses, and unsafe conditions has
decreased and whether there has been compliance with preventative procedures, and to
develop a plan for improved adherence with the continuous quality improvement program in
the future. Each pharmacy shall conduct a quality self-audit upon change of
pharmacist-in-charge to familiarize that person with the pharmacy's continuous quality
improvement program.
6.
Protection from discovery:
a.
Records that are generated as a component of a pharmacy's ongoing quality assurance
program and which are maintained for that program are peer review documents and are
not subject to subpoena or discovery in an arbitration or civil proceeding.
b.
Records that are generated as a component of a pharmacy's ongoing quality assurance
program and which are maintained for that program are confidential and may not be
released, distributed, or communicated in any manner, except as provided by these rules
or the permitee's policies and procedures. Recognizing the importance of sharing
information with staff, experts, consultants, and others is necessary in reducing
medication errors, information used as a part of the permitee's quality program in any
manner does not compromise the confidentiality and privilege of such information.
c.
This subsection does not prohibit a patient from accessing the patient's prescription
records or affect the discoverability of any records that are not generated solely as a
component of a pharmacy's ongoing quality assurance program and maintained solely
for that program.
7.
The board's regulatory oversight activities regarding a pharmacy's continuous quality
improvement program are limited to inspection of the pharmacy's continuous quality
improvement policies and procedures and enforcing the pharmacy's compliance with those
policies and procedures.
8.
An analysis or summary of findings, produced within six months of submission, is evidence of
compliance with the records and data collection provisions. A permittee may not be required to
produce data, charts, error reports, or findings collected and used in compiling an analysis
summary.
9.
Not withstanding subsections 6 and 8, if a pharmacy is reporting to a patient safety
organization whose primary mission is continuous quality improvement all data and records
are privileged and confidential as provided in the Patient Safety and Quality Improvement Act
of 2005 and implementing regulations.